Brigid C. Browne

1.3k citations

22 papers · 969 · h-index 14

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
Immunology and Allergy top 10%
- Cell Adhesion Molecules Research

Papers in

Oncology 18
- HER2/EGFR in Cancer Research 18
- Peptidase Inhibition and Analysis 4
Radiology, Nuclear Medicine and Imaging 8
- Monoclonal and Polyclonal Antibodies Research 8

Co-authors: John Crown (15 shared papers)Norma O’Donovan (18 shared papers)Michael J. Duffy (6 shared papers)Neil A. O’Brien (11 shared papers)Dennis J. Slamon (4 shared papers)Charles Ginther (1 shared paper)Lucy Chow (1 shared paper)Jane Arboleda (1 shared paper)
Journals: Journal of Clinical Oncology (5 papers)Cancer Research (3 papers)European Journal of Cancer (2 papers)Annals of Oncology (2 papers)Current Cancer Drug Targets (1 paper)
Partner nations: Ireland United States Australia

In The Last Decade

Brigid C. Browne

21 papers receiving 958 citations

Peers

Countries citing papers authored by Brigid C. Browne

Since Specialization

Citations

This map shows the geographic impact of Brigid C. Browne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigid C. Browne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigid C. Browne more than expected).

Fields of papers citing papers by Brigid C. Browne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigid C. Browne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigid C. Browne. The network helps show where Brigid C. Browne may publish in the future.

Co-authors

The 25 scholars most cited alongside Brigid C. Browne, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Brigid C. Browne Line = papers co-authored together Brigid C. Browne links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib Molecular Cancer Therapeutics ·Neil A. O’Brien, Brigid C. Browne, Lucy Chow, Yuhua Wang, Charles Ginther, Jane Arboleda, Michael J. Duffy, John Crown, Norma O’Donovan, Dennis J. Slamon	2010	249
2	Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells Cancer Research ·Falko Hochgräfe, Luxi Zhang, Sandra O’Toole, Brigid C. Browne, Mark Pinese, Ana Porta Cubas, Gillian M. Lehrbach, David R. Croucher, Danny Rickwood, Alice Boulghourjian, Robert F. Shearer, Radhika Nair, Alexander Swarbrick, Dana Faratian, Peter Mullen, David J. Harrison, Andrew V. Biankin, Robert L. Sutherland, Mark J. Raftery, Roger J. Daly	2010	141
3	HER-2 Signaling and Inhibition in Breast Cancer Current Cancer Drug Targets ·Brigid C. Browne, Neil A. O’Brien, Michael J. Duffy, John Crown, Norma O’Donovan	2009	92
4	Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer British Journal of Cancer ·Bríd M. Ryan, Norma O’Donovan, Brigid C. Browne, Caroline O'Shea, John Crown, Arnold Hill, E. McDermott, N. J. O’Higgins, Michael J. Duffy	2004	87
5	Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells Annals of Oncology ·Brigid C. Browne, John Crown, Natarajan Venkatesan, Michael J. Duffy, Martin Clynes, Dennis J. Slamon, Norma O’Donovan	2010	84
6	Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway Cancer Research ·David R. Croucher, Falko Hochgräfe, Luxi Zhang, Ling Liu, Ruth J. Lyons, Danny Rickwood, Carole M. Tactacan, Brigid C. Browne, Naveid Ali, Howard Chan, Robert F. Shearer, David Gallego‐Ortega, Darren N. Saunders, Alexander Swarbrick, Roger J. Daly	2013	67
7	Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors Cancer Research ·Sweta Rani, Claire Corcoran, Liam Shiels, Serena Germano, Susan Breslin, Stephen F. Madden, Martina S.J. McDermott, Brigid C. Browne, Norma O’Donovan, John Crown, Martina Gogarty, Annette T. Byrne, Lorraine O’Driscoll	2014	39
8	PP2A inhibition overcomes acquired resistance to HER2 targeted therapy Molecular Cancer ·Martina S.J. McDermott, Brigid C. Browne, Neil T. Conlon, Neil A. O’Brien, Dennis J. Slamon, Michael Henry, Paula Meleady, Martin Clynes, Paul Dowling, John Crown, Norma O’Donovan	2014	39
9	HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells Cancers ·Martina S.J. McDermott, Neil T. Conlon, Brigid C. Browne, Adam Szabo, Naoise C. Synnott, Neil A. O’Brien, Michael J. Duffy, John Crown, Norma O’Donovan	2019	33
10	Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours Breast Cancer Research and Treatment ·Brigid C. Browne, Alex J. Eustace, Susan Kennedy, Neil A. O’Brien, Kasper Pedersen, Martina S.J. McDermott, Annemarie Larkin, Jo Ballot, Thamir Mahgoub, Francesco Sclafani, Stephen F. Madden, John Kennedy, Michael J. Duffy, John Crown, Norma O’Donovan	2012	32
11	Functional characterization of cancer-associated Gab1 mutations Oncogene ·C Ortiz-Padilla, David Gallego‐Ortega, Brigid C. Browne, Falco Hochgräfe, C. Elizabeth Caldon, Ruth J. Lyons, David R. Croucher, Danny Rickwood, Christopher J. Ormandy, Tilman Brummer, Roger J. Daly	2012	26
12	Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells International Journal of Oncology ·Martina S.J. McDermott, Alexandra Canonici, Laura Ivers, Brigid C. Browne, Stephen F. Madden, Neil A. O’Brien, John Crown, Norma O’Donovan	2017	24
13	HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer Investigational New Drugs ·Alexandra Canonici, Laura Ivers, Neil T. Conlon, Kasper Pedersen, Nicola Gaynor, Brigid C. Browne, Neil A. O’Brien, Giuseppe Gullo, Denis M. Collins, Norma O’Donovan, John Crown	2018	21
14	Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation Molecular Biology of the Cell ·Maria Teresa Herrera Abreu, William E. Hughes, Katarina Mele, Ruth J. Lyons, Danny Rickwood, Brigid C. Browne, Haley L. Bennett, Pascal Vallotton, Tilman Brummer, Roger J. Daly	2010	20
15	Effect of afatinib alone and in combination with trastuzumab in HER2-positive breast cancer cell lines. Journal of Clinical Oncology ·Alexandra Canonici, Kasper Pedersen, Brigid C. Browne, Martina S.J. McDermott, Naomi Walsh, John Crown, Norma O’Donovan	2013	5
16	Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer cells. Journal of Clinical Oncology ·Martina S.J. McDermott, Brigid C. Browne, J. Crown, Neil A. O’Brien, DJ Slamon, Norma O’Donovan	2011	3
17	Irreversible panHER tyrosine kinase inhibitors (TKIs) to induce irreversible senescence in HER2 positive breast cancer cells. Journal of Clinical Oncology ·Martina S.J. McDermott, Brigid C. Browne, Adam Szabo, John Crown, Norma O’Donovan	2016	3
18	Alterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (T-ADCC) in a lapatinib-resistant HER2+ breast cancer cell line model Annals of Oncology ·N. Gaynor, M Guibourdenche, Brigid C. Browne, Lorraine O’Driscoll, Neil A. O’Brien, Norma O’Donovan, John Crown, Denis M. Collins	2017	1
19	Pre-clinical evaluation of the PP2A inhibitor LB-100 for the treatment of lapatinib resistant HER2-positive breast cancer. Journal of Clinical Oncology ·Neil T. Conlon, Martina S.J. McDermott, Brigid C. Browne, Sandra Roche, Fiona O’Neill, Justine Meiller, Alex J. Eustace, Denis M. Collins, Norma O’Donovan, John Crown	2018	1
20	145 PP2A – a Novel Target for the Treatment of Lapatinib-resistant Breast Cancer European Journal of Cancer ·Martina S.J. McDermott, Brigid C. Browne, NA O'Brien, Dennis J. Slamon, Mélissa Henry, Paula Meleady, Martin Clynes, Paul Dowling, J. Crown, Norma O’Donovan	2012	1

About Brigid C. Browne

Brigid C. Browne is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Pulmonary and Respiratory Medicine and Genetics, having authored 22 papers that have together received 969 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Lung Cancer Treatments and Mutations (4 papers), Chronic Lymphocytic Leukemia Research (4 papers), Advanced Breast Cancer Therapies (4 papers), Peptidase Inhibition and Analysis (4 papers), Growth Hormone and Insulin-like Growth Factors (3 papers) and Protein Tyrosine Phosphatases (2 papers). The work is most often cited by research in Oncology (570 citations), Immunology and Allergy (72 citations), Radiology, Nuclear Medicine and Imaging (198 citations), Cancer Research (129 citations) and Genetics (85 citations). Brigid C. Browne has collaborated with scholars based in Ireland, United States and Australia. Frequent co-authors include John Crown, Norma O’Donovan, Michael J. Duffy, Neil A. O’Brien, Dennis J. Slamon, Charles Ginther, Lucy Chow, Jane Arboleda, Yuhua Wang and Martina S.J. McDermott. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, European Journal of Cancer, Annals of Oncology and Current Cancer Drug Targets.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Brigid C. Browne

Impact in

Papers in i

In The Last Decade

Brigid C. Browne

Peers

Countries citing papers authored by Brigid C. Browne

Fields of papers citing papers by Brigid C. Browne

All Works

About Brigid C. Browne

Explore authors with similar magnitude of impact

Papers in